Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats

Pain

Volumn 84, Issue 2-3, 2000, Pages 421-428

  Ross, Fraser B ^a   Wallis, Steven C ^a   Smith, Maree T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Opioid agonist; Opioid agonist; Morphine; Opioid synergy; Oxycodone

Indexed keywords

KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONAZINE; NORBINALTORPHIMINE; OXYCODONE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CENTRAL NERVOUS SYSTEM DEPRESSION; CONTROLLED STUDY; DRUG POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; SIDE EFFECT;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MORPHINE; NOCICEPTORS; OXYCODONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033968760     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00230-4     Document Type: Article

References (24)

1. Beaver W.T., Wallenstein S.L., Houde R.W., Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol. 17:1977;186-198.
2. Brady L.S., Holtzmann S.G. Analgesic effects of intraventricular morphine and enkephalins in non-dependent and morphine-dependent rats. J Pharmacol Exp Ther. 222:1982;190-197.
3. Butelman E.R., Negus S.S., Ai Y., de-Costa B.R., Woods J.H. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther. 267:1993;1269-1276.
4. Cleary J., Mikus G., Somogyi A., Bochner F. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther. 271:1994;1528-1534.
5. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J Pharmacol Exp Ther. 72:1941;74-79.
6. Hahn E.F., Nishimura S., Goodman R.R., Pasternak G.W. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones. J Pharmacol Exp Ther. 235:1985;839-845.
7. Horan P., de-Costa B.R., Rice K.C., Porrcca F. Differential antagonism of U69, 593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice. J Pharmacol Exp Ther. 257:1991;1154-1161.
8. Kaiko R.F., Benziger D.P., Fitzmartin R.D., Burke B.E., Reder R.F., Goldenheim P.D. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther. 59:1996;52-61.
9. Lacouture P.G., Iwan T., Benziger D., Fitzmartin R., Cheng C., Hou Y., Kaiko R.F. Plasma disposition of oxycodone (OC), oxymorphone (OM), and noroxycodone (NO) with longterm controlled-release (CR) oxycodone (Oxycontin™ Tablets) dosing, Proc. 8th World Congress on Pain, 286. 1996;IASP Press. Abstr.
10. Leighton G.E., Rodriguez R.E., Hill R.G., Hughs J. Kappa-Opoid agonists produce antinociception after i.v. and icv but not intrathecal administration in the rat. Br J Pharmacol. 93:1988;553-560.
11. Leow K.P., Smith M.T. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci. 54:1994;1229-1236.
12. Ling G.S., Pasternak G.W. Morphine catalepsy in the rat: involvement of mu 1 (high affinity) opioid binding sites. Neurosci Lett. 32:1982;193-196.
13. Miaskowski C., Sutters K.A., Taiwo Y.O., Levine J.D. Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists. Pain. 49:1992;137-144.
14. Miaskowski C., Taiwo Y.O., Levine J.D. Antinociception produced by receptor selective opioids.Modulation of supraspinal antinociceptive effects by spinal opioids. Brain Res. 608:1993;87-94.
15. Muralidharan G.K., Midha K., McKay G., Hawes E.M., Inaba T. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica. 19:1989;189-197.
16. Paxinos G., Watson G. The rat brain in stereotaxic coordinates. 2 :1986;Academic Press Inc, San Diego.
17. Pick C.G., Roques B., Gacel G., Pasternak G.W. Supraspinal mu 2-opioid receptors mediate spinal/supraspinal morphine synergy. Eur J Pharmacol. 220:1992;275-277.
18. Pöyhia R., Kalso E.A. Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol. 70:1992;125-130.
19. Ross F.B., Smith M.T. The intrinsic antinociceptive effects of oxycodone appear to be kappa opioid receptor mediated. Pain. 73:1997;151-157.
20. Sutters K.A., Miaskowski C., Taiwo Y.O., Levine J.D. Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids. Brain Res. 530:1990;290-294.
21. Tallarida R.J., Porreca F., Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 45:1989;947-961.
22. World Health Organization. Cancer pain relief program, WHO, Geneva, Switzerland, (1986).
23. Xu B.Q., Aasmundstad T.A., Bjorneboe A., Christophersen A.S., Morland J. Ethylmorphine O-deethylation in isolated rat hepatocytes. Involvement of codeine O-demethylation enzyme systems. Biochem Pharmacol. 49:1995;453-460.
24. Yeung J.C., Rudy T.A. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther. 215:1980;633-642.